Morningstar

United Therapeutics Corp UTHR

Morningstar Rating
Unlock
Stock XNAS Rating as of
$591.11 −1.85 (0.31%)
View Full Chart
As of Cboe BZX Real-Time Price Closed

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
UTHR is trading at a LOCK|D!?b@z premium.
Price
$593.40
Fair Value
LOCK|?.zp@F$N^<
Uncertainty
LOCK|<V
1-Star Price
LOCK|z.fT#g!@
5-Star Price
LOCK|j.?YL%T@
Economic Moat
LOCK|Vn@W!
Capital Allocation
LOCK|y#>rXR

News

View All

Trading Information

Previous Close Price
$593.31
Day Range
$587.24–598.83
52-Week Range
$457.18–614.17
Bid/Ask
$549.00 / $630.00
Shares Outstanding
42.59M
Market Cap
$25.36B
Volume/Avg
261,405 / 693,580

Key Statistics

Price/Earnings (Normalized)
22.43
Price/Sales
8.64
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
8.13%

Company Profile

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
1,400
Website
https://www.unither.com

Valuation

View More
Metric
UTHR
Price/Earnings (Normalized)
22.43
Price/Book Value
4.01
Price/Sales
8.64
Price/Cash Flow
15.98
Price/Earnings
UTHR

Financial Strength

Metric
UTHR
Quick Ratio
3.87
Current Ratio
4.61
Interest Coverage
115.08
Quick Ratio
UTHR

Profitability

Metric
UTHR
Return on Assets (Normalized)
18.03%
Return on Equity (Normalized)
20.23%
Return on Invested Capital (Normalized)
18.48%
Return on Assets
UTHR

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|SPf&pRsLOCK|s%yc$71B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|RlBG$?HxLOCK|Vv$&$51B
Haleon PLC ADR
HLN
LOCK|YbY$LQLOCK|$$$40B
Zoetis Inc Class A
ZTS
LOCK|dcjF&VXLOCK|lt@$34B
Viatris Inc
VTRS
LOCK|Hn?HJKLOCK|M$y$24B
Elanco Animal Health Inc
ELAN
LOCK|#^NLOCK|wZB$13B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|%@b^wZLOCK|Gf$12B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|hm?mRJ$LOCK|TT$$5B
Perrigo Co PLC
PRGO
LOCK|<RPyHMRLOCK|?#$2B
Prestige Consumer Healthcare Inc
PBH
LOCK|cT>?FqLOCK|pH>y$2B

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.